Regeneron (REGN) Tops Q2 EPS by 104c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Pharma (REGN) PT Raised to $472 at Goldman Sachs
August 4, 2017 7:00 AM EDTGoldman Sachs raised its price target on Regeneron Pharma (NASDAQ: REGN) to $472.00 (from $469.00) while maintaining a Neutral rating.
... MoreRegeneron Pharma (REGN) PT Raised to $455 at JPMorgan
August 4, 2017 6:58 AM EDTJPMorgan raised its price target on Regeneron Pharma (NASDAQ: REGN) to $455.00 (from $427.00) while maintaining a Neutral rating.
... MoreRegeneron Pharma (REGN) PT Raised to $580 at Leerink Partners
August 4, 2017 6:55 AM EDTLeerink Partners raised its price target on Regeneron Pharma (NASDAQ: REGN) to $580.00 (from $573.00) while maintaining a Outperform rating.
... MoreRegeneron Pharma (REGN) PT Raised to $575 at Citi
August 4, 2017 6:53 AM EDTCiti raised its price target on Regeneron Pharma (NASDAQ: REGN) to $575.00 (from $555.00) while maintaining a Buy rating.
... More